The discovery of cyclin-dependent kinases 4/6 (CDK4/6) inhibitors significantly reshaped the therapeutic landscape of hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (aBC)1. Here, CDK4 is linked to breast cancer.